Product Name: Myd88 (Phospho-Tyr257) Rabbit Polyclonal Antibody
Catalog #: APRab05811

Summary

Production Name	Myd88 (Phospho-Tyr257) Rabbit Polyclonal Antibody
Description	Rabbit Polyclonal Antibody
Host	Rabbit
Application	WB
Reactivity	Human,Mouse,Rat

Performance

Conjugation	Unconjugated
Modification	Phosphorylated
Isotype	IgG
Clonality	Polyclonal
Form	Liquid
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Buffer	Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type preservative N.
Purification	Affinity purification

Immunogen

Gene Name	MYD88
Alternative Names	Myeloid differentiation primary response protein MyD88
Gene ID	4615.0
SwissProt ID	Q99836.

Application

Dilution Ratio	WB 1:500-2000
Molecular Weight	33kDa

Background

Product Name: Myd88 (Phospho-Tyr257) Rabbit Polyclonal Antibody
Catalog #: APRab05811

disease:Defects in MYD88 are the cause of MYD88 deficiency (MYD88D) [MIM:612260]; also called recurrent pyogenic bacterial infections due to MYD88 deficiency. Patients suffer from autosomal recessive, life-threatening, often recurrent pyogenic bacterial infections, including invasive pneumococcal disease, and die between 1 and 11 months of age. Surviving patients are otherwise healthy, with normal resistance to other microbes, and their clinical status improved with age.,function:Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response. Acts via IRAK1, IRAK2 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. May be involved in myeloid differentiation.,similarity:Contains 1 death domain.,similarity:Contains 1 TIR domain.,subunit:Homodimer. Also forms heterodimers with TIRAP. Binds to TLR2, TLR4, IRAK1 and IRAK2 via their respective TIR domains. Interacts with IL1RL1.,tissue specificity:Ubiquitous.,

Research Area

Image Data



Western Blot analysis of 1 A431 cell, 2 Serum-free treated ,using primary antibody at 1:1000 dilution. Secondary antibody was diluted at 1:10000

Note

For research use only.